Compare UVE & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVE | ABUS |
|---|---|---|
| Founded | 1990 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 957.6M | 848.8M |
| IPO Year | 1996 | 2008 |
| Metric | UVE | ABUS |
|---|---|---|
| Price | $36.91 | $4.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $40.00 | $5.00 |
| AVG Volume (30 Days) | 156.4K | ★ 1.2M |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.97% | N/A |
| EPS Growth | ★ 214.43 | 55.26 |
| EPS | ★ 1.88 | 0.87 |
| Revenue | ★ $1,603,915,000.00 | $14,083,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.88 | $239.71 |
| P/E Ratio | $20.02 | ★ $5.28 |
| Revenue Growth | 5.48 | ★ 128.21 |
| 52 Week Low | $21.96 | $3.04 |
| 52 Week High | $41.96 | $5.10 |
| Indicator | UVE | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 40.68 | 57.10 |
| Support Level | $32.51 | $4.16 |
| Resistance Level | $41.32 | $4.60 |
| Average True Range (ATR) | 1.16 | 0.18 |
| MACD | -0.45 | 0.04 |
| Stochastic Oscillator | 1.98 | 67.81 |
Universal Insurance Holdings Inc is an insurance holding company. Through its subsidiaries, the company mainly offers property and casualty insurance and value-added insurance services. It develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners lines of business and performs all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The group offers the following types of personal residential insurance: homeowners, renters/tenants, condo unit owners, and dwelling/fire, through an independent agent network and online distribution channels across multiple states in the United States of America.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.